Related Experiment Videos
[Cyclophosphamide bolus therapy in lupus nephritis]
1Abteilung für Immunologie und Transfusionsmedizin, Universität Hamburg.
Deutsche Medizinische Wochenschrift (1946)
|July 16, 1993
Summary
Intravenous pulse cyclophosphamide is effective for lupus nephritis remission. Treatment duration exceeding three months is crucial for achieving remission and preventing disease progression in most patients.
Area of Science:
- Nephrology
- Rheumatology
- Immunology
Background:
- Lupus nephritis is a severe complication of systemic lupus erythematosus.
- Optimal treatment duration for cyclophosphamide in lupus nephritis remains unclear.
Purpose of the Study:
- To determine the required number of intravenous pulse cyclophosphamide cycles for lupus nephritis remission.
- To compare treatment efficacy between a 3-month and an extended treatment protocol.
Main Methods:
- Pilot study with 21 lupus nephritis patients randomized into two groups (3 months vs. >12 months treatment).
- Intravenous pulse cyclophosphamide dosage escalated from 500 mg/m2 to 1000 mg/m2 based on WBC count.
- Remission, disease progression, and side effects were monitored.
Main Results:
- 15 out of 18 evaluable patients achieved remission after an average of 7.3 cycles.
- Remission was achieved in only one patient in the 3-month group, while several in the extended group stopped treatment early due to remission.
- Disease progressed in two patients, and one patient died. Side effects included infections and leukopenia.
Conclusions:
- Intravenous pulse cyclophosphamide is an effective treatment for lupus nephritis.
- Treatment must be continued for longer than 3 months to achieve optimal remission rates.
- Extended treatment duration appears necessary for sustained remission and improved outcomes in lupus nephritis.